Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus tislelizumab in advanced colorectal cancer after failure of third-line treatment
ChiCTR2200059848Phase 4Not yet recruiting
- Sponsor
- Anhui Cancer Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib and tislelizumab in colorectal cancer (CRC), sponsored by Anhui Cancer Hospital. Primary endpoint: Progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
surufatinibtislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200059848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059848.